NYSE:HIMSHealthcare
Why Hims & Hers Health (HIMS) Is Up 14.6% After Entering Low Testosterone Care With KYZATREX and At-Home Testing
Hims & Hers Health, Inc. recently announced an exclusive partnership with Marius Pharmaceuticals to expand into the men's health market by offering innovative, affordable, and personalized low testosterone treatment plans, including the FDA-approved oral testosterone KYZATREX® and at-home blood testing starting in 2026.
This move positions Hims & Hers to address an estimated 20 million men in the US affected by low testosterone, diversifying its offerings well beyond its core sexual health...